

COPY

28967/35061A

8/16/00 / 12



The Patent Office is hereby requested to acknowledge receipt of the following papers by stamping and returning this card.

Alitalo et al.

09/427,657

Information Disclosure Statement w/Form
PTO-1449 w/25US,15FOR,880TH

with certificate of mailing dated: August 16, 2000.



MARSHALL O'TOOLE
MARSHALL, O'TOOLE, GERSTEIN, MURRAY & BORUN

6300 SEARS TOWER

233 SOUTH WACKER DRIVE

CHICAGO, ILLINOIS 60606-6402

13




COPY

PATENT

Docket No. 28967/35061A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Alitalo et al.) I hereby certify that this paper and the
Serial No.: 09/427,657) papers referred to as attached are being
Filed: Oct 26, 1999) deposited with the United States Postal
For: "USE OF VEGF-C OR) Service, as first class mail, postage prepaid,
VEGF-D GENE OR) in an envelope addressed to the Assistant
PROTEIN TO PREVENT) Commissioner of Patents, Washington,
RESTENOSIS") D.C., 20231 on August 16, 2000
Group Art Unit: 1633) 
Examiner: To be determined) R. Minako Pazdera
) (Reg. No. P46,984)

**INFORMATION DISCLOSURE STATEMENT AND
ACCOMPANYING FORM PTO-1449**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


In compliance with 37 C.F.R. §1.97 and the continuing duty of disclosure under 37 C.F.R. §1.56, the attached Form PTO-1449 and a copy of the documents cited therein are hereby submitted by Applicants for consideration in connection with the above-identified patent application.

This statement and the Form PTO-1449 are submitted before receipt of a first Office Action in the above-identified patent application. Accordingly, it is submitted that no fee is due in this matter under 37 C.F.R. §1.97(b). However, if it is determined that any appropriate fee is due, please charge Deposit Account No. 13-2855. A duplicate of this paper is enclosed.

Respectfully submitted,

**MARSHALL, O'TOOLE, GERSTEIN,
MURRAY & BORUN**

By


R. Minako Pazdera (Reg. No. P46,984)
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606
(312) 474-6300

August 16, 2000

COPY

SHEET 1 of 10

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.
28967/35061A

Serial No.
09/427,657

Applicant
Alitalo et al.

Filing Date
Oct 26, 1999

Group
1633

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	A1	5,087,244	02/11/92	Wolinsky et al.	604	33	
	A2	5,631,237	05/20/97	Dzau et al.	514	44	
	A3	5,653,689	08/05/97	Buelna et al.	604	96	
	A4	5,674,192	10/07/97	Sahatjian et al.	604	28	
	A5	5,679,400	10/21/97	Tuch	427	2.14	
	A6	5,697,967	12/16/97	Dinh et al.	623	1	
	A7	5,700,286	12/23/97	Tartaglia et al.	623	1	
	A8	5,707,385	01/13/98	Williams et al.	606	192	
	A9	5,713,860	02/03/98	Kaplan et al.	604	96	
	A10	5,749,848	05/12/98	Jang et al.	604	53	
	A11	5,776,184	07/07/98	Tuch	623	1	
	A12	5,776,755	07/07/98	Alitalo et al.	435	194	
	A13	5,779,729	07/14/98	Severini	606	191	
	A14	5,785,965	07/28/98	Pratt et al.	424	93.21	
	A15	5,792,453	08/11/98	Hammond et al.	424	93.21	
	A16	5,795,898	08/18/98	Brown et al.	514	263	
	A17	5,799,384	09/01/98	Schwartz et al.	29	458	
	A18	5,800,507	09/01/98	Schwartz et al.	623	1	
	A19	5,824,048	10/20/98	Tuch	623	1	
	A20	5,830,879	11/03/98	Isner et al.	514	44	


EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY

SHEET 2 of 10

Form PTO-1449 (Modified) <div style="text-align: center;">  </div>	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 28967/35061A	Serial No. 09/427,657
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		Applicant Alitalo et al.	
		Filing Date Oct 26, 1999	Group 1633

U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	A21	5,924,048	07/13/99	McCormack <i>et al.</i>	702	13	
	A22	5,932,540	08/03/99	Hu <i>et al.</i>	514	2	
	A23	5,935,820	08/10/99	Hu <i>et al.</i>	435	69.4	
	A24	5,994,300	11/30/99	Bayne, <i>et al.</i>	514	12	
	A25	6,040,157	03/21/00	Hu <i>et al.</i>	435	69.4	

FOREIGN PATENT DOCUMENTS								
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
	B1	95/24473	09/14/95	WO				
	B2	96/24473	09/14/95	WO				
	B3	96/39515	12/12/96	WO				
	B4	97/05250	02/13/97	WO				
	B5	97/09427	03/13/97	WO				
	B6	97/17359	05/15/97	WO				
	B7	97/17442	05/15/97	WO				
	B8	98/07832	02/26/98	WO				
	B9	98/19712	05/14/98	WO				
	B10	98/20027	05/14/98	WO				
	B11	98/24811	06/11/98	WO				
	B12	98/33917	08/06/98	WO				

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

28967/35061A

Serial No.

09/427,657

INFORMATION DISCLOSURE STATEMENT

Applicant

Alitalo et al.


Filing Date

Oct 26, 1999

Group

1633

(use several sheets if necessary)



FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
	B13	98/49300	11/05/98	WO				
	B14	99/07844	02/18/99	WO				
	B15	99/46364	09/16/99	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C1	Achen, M.G. <i>et al.</i> , "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)," <i>Proc. Natl. Acad. Sci. USA</i> 95(2):548-553 (January, 1998).
	C2	Alitalo <i>et al.</i> , "Vascular Endothelial Growth Factors B and C and Receptors Involved in Angiogenesis," <i>German-American Academic Council Foundation (GAAC)/ Stiftung Deutsch-Amerikanisches Akademisches Konzil (DAAK), 2nd Symposium on Current Problems in Molecular Medicine: The Role of Cytokines in Human Disease</i> , November 17-20, 1996, Ringberg Castle, Germany, p. 1 (ABSTRACT).
	C3	Asahara, <i>et al.</i> , "Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF ₁₆₅ gene transfer," <i>Circulation</i> 94:3291-3302 (1996).
	C4	Asahara, <i>et al.</i> , "Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery," <i>Circulation</i> 91:2793-2801 (1995).
	C5	Barr, <i>et al.</i> , "Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus," <i>Gene Ther.</i> 1:51-58 (1994).
	C6	Boshart, <i>et al.</i> , "A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus," <i>Cell</i> 41:521-530 (June, 1985).
	C7	Callow, <i>et al.</i> , "Vascular permeability factor accelerates endothelial regrowth following balloon angioplasty," <i>Growth Factors</i> 10:223-228 (1994).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY

SHEET 4 of 10

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.
28967/35061A

Serial No.
09/427,657

Applicant
Alitalo et al.

Filing Date
Oct 26, 1999

Group
1633

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C8	Camenzind <i>et al.</i> , "Use of Locally Delivered Conventional Drug Therapies," <i>Semin Intervent Cardiol</i> 1:67-76 (1996).
	C9	Cao, <i>et al.</i> , "Vascular endothelial growth factor-C induces angiogenesis <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci.</i> 95:14389-14394 (1998).
	C10	Cerek, <i>et al.</i> , "Growth factors in pathogenesis of coronary arterial restenosis," <i>Am. J. Cardiol.</i> 68:24C-33C (November, 1991).
	C11	Chang, <i>et al.</i> , "Gene therapy for vascular proliferative disorders," <i>Semin. Intervent. Cardiol.</i> 1:185-193 (1996).
	C12	Darius, <i>et al.</i> , "Lokale Medikamentengabe und Genterapie," <i>Herz</i> 22:347-54 (1997).
	C13	Davis, <i>et al.</i> , "Direct gene transfer into skeletal muscle <i>in vivo</i> : factors affecting efficiency of transfer and stability of expression," <i>Hum. Gene Ther.</i> 4:151-9 (1993).
	C14	Debbas, <i>et al.</i> , "Stenting within a stent: Treatment for repeat in-stent restenosis in a venous graft," <i>American Heart Journal</i> 133:460-468 (April, 1997).
	C15	De Meyer, <i>et al.</i> , "Mechanisms of neointima formation-lessons from experimental models," <i>Vasc. Med.</i> 2:179-189 (1997).
	C16	DeYoung, <i>et al.</i> , "Gene therapy for restenosis: Are we ready?," <i>Circ. Res.</i> 82:306-313 (1998).
	C17	Dignam, <i>et al.</i> , "Balbani ring 3 in <i>Chironomus tentans</i> encodes a 185-kDa secretory protein which is synthesized throughout the fourth larval instar," <i>Gene</i> 88:133-140 (1990).
	C18	Enholm, <i>et al.</i> , "Vascular endothelial growth factor-C, a growth factor for lymphatic endothelial cells," <i>Trends in Cardiovascular Med.</i> 8:292-297 (1998).
	C19	Enholm, <i>et al.</i> , "Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia," <i>Oncogene</i> 14:2475-2483 (1997).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28967/35061ASerial No.
09/427,657

INFORMATION DISCLOSURE STATEMENT

Applicant
Alitalo et al.Filing Date
Oct 26, 1999Group
1633

(Use several sheets if necessary)



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C20	Feldman, <i>et al.</i> , "Perspectives of arterial gene therapy for the prevention of restenosis," <i>Cardiovascular Research</i> 32:194-207 (1996).
C21	Ferrara, <i>et al.</i> , "Clinical applications of angiogenic growth factors and their inhibitors," <i>Nature Med</i> 5:1359-64 (December 1999).
C22	GenBank Accession No. AJ000185 Homo sapiens mRNA for vascular endothelial growth factor-D.
C23	GenBank Accession No. AF014827 Rattus norvegicus vascular endothelial growth factor-D (VEGF-D) mRNA, complete cds.
C24	GenBank Accession No. MMU73620 Mus musculus VEGF-C mRNA, complete cds.
C25	GenBank Accession No. CCY15837 Coturnix coturnix mRNA for vascular endothelial growth factor C.
C26	GenBank Accession No. D89628 Mus musculus mRNA for vascular endothelial growth factor D, complete cds.
C27	GenBank Accession No. X94216 H. sapiens mRNA for VEGF-C protein.
C28	Gnatenko, <i>et al.</i> , "Characterization of recombinant adeno-associated virus-2 as a vehicle for gene delivery and expression into vascular cells," <i>J. Investig. Med.</i> 45:87-89 (1997).
C29	Grosskreutz, <i>et al.</i> , "Vascular endothelial growth-factor-induced migration of vascular smooth muscle cells in vitro," <i>Microvasc. Res.</i> 58(2):128-136 (1999).
C30	Hu, <i>et al.</i> , "A novel regulatory function of proteolytically cleaved VEGF-2 for vascular endothelial and smooth muscle cells," <i>FASEB J.</i> 11:498-504 (1997).
C31	International Search Report for PCT/US99/24054.
C32	Isner, <i>et al.</i> , "Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease," <i>Circulation</i> 91:2687-2692 (1995).
C33	Isner, <i>et al.</i> , "Arterial gene therapy for restenosis," <i>Human Gene Therapy</i> 7:989-1011 (May, 1996).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

28967/35061A

Serial No.

09/427,657

INFORMATION DISCLOSURE STATEMENT

Applicant

Alitalo et al.


Filing Date

Oct 26, 1999

Group

1633

(Use several sheets if necessary)



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C34	Jeltsch, <i>et al.</i> , "Hyperplasia of lymphatic vessels in VEGF-C transgenic mice," <i>Science</i> 276:1423-1425 (1997).
C35	Joukov, <i>et al.</i> , "Vascular endothelial growth factors VEGF-B and VEGF-C," <i>J. Cell Physiol</i> 173:211-215 (1997).
C36	Joukov, <i>et al.</i> , "Proteolytic processing regulates receptor specificity and activity of VEGF-C," <i>EMBO J.</i> 16(13):3898-3911 (1997).
C37	Joukov, <i>et al.</i> , "A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities," <i>J. Biol. Chem.</i> 273(12):6599-6602 (March, 1998).
C38	Joukov, <i>et al.</i> , "A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases," <i>EMBO J.</i> 15:290-298 (1996).
C39	Jussila, <i>et al.</i> , "Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3," <i>Cancer Res.</i> 58(8):1599-604 (1998).
C40	Kagan, <i>et al.</i> , "Mediators of restenosis," <i>Surgical Clinics of North America</i> 78:481-500 (June, 1998).
C41	Kim, <i>et al.</i> , "Minimal requirements for lentivirus vector based on human immunodeficiency virus type 1," <i>J. Virol.</i> 72(1):811-816 (January, 1998).
C42	Kingsman <i>et al.</i> , "A new generation of gene therapy vectors," <i>Scrip Magazine</i> 43-46 (October, 1998).
C43	Korhonen, <i>et al.</i> , "Endothelial-specific gene expression directed by the tie gene promoter in vivo," <i>Blood</i> 86(5):1828-1835 (September, 1995).
C44	Kukk, <i>et al.</i> , "VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development," <i>Development</i> 122:3829-3839 (1996).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28967/35061ASerial No.
09/427,657

INFORMATION DISCLOSURE STATEMENT

Applicant
Alitalo et al.Filing Date
Oct 26, 1999Group
1633

(Use several sheets if necessary)



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C45	Laitinen, <i>et al.</i> , "VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries," <i>Hum. Gene Ther</i> 8:1737-1744 (October, 1997).
C46	Laitinen, <i>et al.</i> , "Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia," <i>Hum. Gene Ther.</i> 9:1481-1486 (July, 1998).
C47	Laitinen, <i>et al.</i> , "Adventitial gene transfer to arterial wall," <i>Pharmacol Res</i> 37:251-254 (1998).
C48	Lambert, <i>et al.</i> , "Local drug delivery catheters: functional comparison of porous and microporous designs," <i>Coron. Artery Dis.</i> 4:469-475 (1993).
C49	Lee, <i>et al.</i> , "Vascular endothelial growth factor-related protein: A ligand and specific activator of the tyrosine kinase receptor Flt4," <i>Proc. Natl. Acad. Sci. USA</i> 93:1988-1992 (1996).
C50	Lehner, <i>et al.</i> , "Comparative sequence analysis of human cytomegalovirus strains," <i>J. Clin. Microbiol.</i> 29:2494-2502 (November, 1991).
C51	Libby, "Gene therapy of restenosis: Promise and Perils," <i>Circ. Res.</i> 82:404-406 (1998).
C52	Lincoff, <i>et al.</i> , "Local drug delivery for the prevention of restenosis: Fact, Fancy, and Future," <i>Circulation</i> 90:2070-2084 (1994).
C53	Lymboussaki, <i>et al.</i> , "Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors," <i>Am J. Path</i> 153:395-403 (August, 1998).
C54	Marchió, <i>et al.</i> , "Vascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi's sarcoma cells," <i>J. Biol. Chem.</i> 274:27617-27622 (September, 1999).
C55	Mazur, <i>et al.</i> , "Coronary restenosis and gene therapy," <i>Texas Heart Institute Journal</i> 21:104-111 (1994).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28967/35061ASerial No.
09/427,657

INFORMATION DISCLOSURE STATEMENT

Applicant
Alitalo et al.Filing Date
Oct 26, 1999Group
1633

(Use several sheets if necessary)



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C56	Morishita, <i>et al.</i> , "Contribution of a vascular modulator, hepatocyte growth factor (HGF), to the pathogenesis of cardiovascular disease," <i>J. Atherosclerosis and Thrombosis</i> 4(3):128-134 (1998).
C57	Mulligan, "The basic science of gene therapy," <i>Science</i> 260:926-932 (May, 1993).
C58	Narins, <i>et al.</i> , "A call for provisional stenting: The balloon in back," <i>Circulation</i> 97:1298-1305 (1998).
C59	Oh, <i>et al.</i> , "VEGF and VEGF-C: Specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane," <i>Dev. Biol.</i> 188:96-109 (1997).
C60	Ohno, <i>et al.</i> , "Gene therapy for vascular smooth muscle cell proliferation after arterial injury," <i>Science</i> 265:781-784 (August, 1994).
C61	Paavonen <i>et al.</i> , "Chromosomal Localization and Regulation of Human Vascular Endothelial Growth Factors B and C (VEGF-B and VEGF-C)," <i>IX International Vascular Biology Meeting</i> , Seattle, Washington, September 4-8, 1996, p. 76 (ABSTRACT 299).
C62	Paavonen <i>et al.</i> , "Novel Human Vascular Endothelial Growth Factor Genes VEGF-B and VEGF-C Localize to Chromosomes 11q13 and 4q34, Respectively," <i>Circulation</i> 93(6):1079-1082 (March 15, 1996).
C63	Paulsson, <i>et al.</i> , "The Balbiani ring 3 gene in <i>Chironomus tentans</i> has diverged repetitive structure split by many introns," <i>J. Mol. Biol.</i> 211:331-349 (1990).
C64	Pepper, <i>et al.</i> , "Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity," <i>J. Cell Physiol.</i> 177:439-452 (1998).
C65	Quantin, <i>et al.</i> , "Adenovirus as an expression vector in muscle cells in vivo," <i>Proc. Natl. Acad. Sci. USA</i> 89:2581-2584 (April, 1992).
C66	Riessen, <i>et al.</i> , "Arterial gene transfer using pure DNA applied directly to a hydrogel-coated angioplasty balloon," <i>Human Gene Therapy</i> 4:749-758 (1993).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28967/35061ASerial No.
09/427,657

INFORMATION DISCLOSURE STATEMENT

Applicant
Alitalo et al.Filing Date
Oct 26, 1999Group
1633

(Use several sheets if necessary)



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C67	Riessen, <i>et al.</i> , "Prospects for site-specific delivery of pharmacologic and molecular therapies," <i>J. Am. Coll. Cardiol.</i> 23:1234-1244 (April, 1994).
C68	Rosenfeld, <i>et al.</i> , "In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium," <i>Cell</i> 68:143-155 (January, 1992).
C69	Salven, <i>et al.</i> , "Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors," <i>Am. J. Pathol.</i> 153:103-108 (1998).
C70	Sambrook <i>et al.</i> , <i>Molecular Cloning: A Laboratory Manual</i> , 2nd ed., Cold Spring Harbor Laboratory Press, § 9.47-9.51 (1989).
C71	Schwartz, "The vessel wall reaction in restenosis," <i>Semin Intervent Cardiol</i> 2:83-88 (1997).
C72	Serruys, <i>et al.</i> , "Heparin-coated Palmaz-Schatz stents in human coronary arteries," <i>Circulation</i> 93:412-422 (1996).
C73	Shih, <i>et al.</i> , "Focal accumulation of an apolipoprotein B-based synthetic oligopeptide in the healing rabbit arterial wall," <i>Proc Natl. Acad Sci. USA</i> 87:1436-1440 (February, 1990).
C74	Steg, <i>et al.</i> , "Arterial gene transfer to the rabbit endothelial and smooth muscle cells using percutaneous delivery of an adenoviral vector," <i>Circulation</i> 90:1648-1656 (1994).
C75	Steg, <i>et al.</i> , "Reduction of restenosis after angioplasty in a atheromatous rabbit model by suicide gene therapy," <i>Circulation</i> 96:408-411 (1997).
C76	Stratford-Perricaudet, <i>et al.</i> , "Widespread long-term gene transfer to mouse skeletal muscles and heart," <i>J. Clin. Invest.</i> 90:626-630 (August, 1992).
C77	Turunen, <i>et al.</i> , "Efficient adventitial gene delivery to rabbit carotid artery with cationic polymer - plasmic complexes," <i>Gene Therapy</i> 6:6-11 (1999).
C78	Van Belle, <i>et al.</i> , "Passivation of metallic stents after arterial gene transfer of pVEGF ₁₆₅ inhibits thrombus formation and intimal thickening," <i>J. Am. Coll. Cardiol.</i> 29:1371-1379 (May, 1997).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY

SHEET 10 of 10

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

28967/35061A

Serial No.

09/427,657

INFORMATION DISCLOSURE STATEMENT

Applicant

Alitalo et al.


Filing Date

Oct 26, 1999

Group

1633

(Use several sheets if necessary)



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C79	Valtola, <i>et al.</i> , "VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer," <i>Am. J. Pathol.</i> 154:1381-1390 (May 1999).
C80	Wang, <i>et al.</i> , "Signal transduction in human hematopoietic cells by vascular endothelial growth factor related protein, a novel ligand for the FLT4 receptor," <i>Blood</i> 90(9):3507-15 (1997).
C81	Wartiovaara, <i>et al.</i> , "Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation," <i>Thromb. Haemost.</i> 80:171-175 (1998).
C82	Wilensky, <i>et al.</i> , "Methods and devices for local drug delivery in coronary and peripheral arteries," <i>Trends Cardiovasc. Med.</i> 3:163-170 (1993).
C83	Willard, <i>et al.</i> , "Genetic modification of the vessel wall," <i>Circulation</i> 89:2190-2197 (1994).
C84	Witzenbichler, <i>et al.</i> , "Bioactivity of vascular endothelial growth factor-2 (=VEGF-C) in vitro and in vivo following intraarterial administration of recombinant protein or intravascular gene transfer in a rabbit ischemic hindlimb model," <i>Eur Heart J.</i> 18:suppl. p.5 (1997).
C85	Wolinsky, <i>et al.</i> , "Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery," <i>J. Am. Coll. Cardiol.</i> 15:475-481 (February, 1990).
C86	Ylä-Herttuala, <i>et al.</i> , "Biochemical composition of coronary arteries in Finnish children," <i>Arteriosclerosis</i> 6:230-236 (March/April, 1986).
C87	Ylä-Herttuala, "Gene therapy for cardiovascular diseases," <i>Ann Med</i> 28:89-93 (1996).
C88	Ylä-Herttuala, "Vascular gene transfer," <i>Curr Opin Lipidol</i> 8:72-76 (1997).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.